Collectively, our findings provide encouraging evidence of a new therapeutic target to inhibit CSCs-mediated ovarian cancer initiation and progression towards the IL-23/IL-23R/STAT3/NF-κB axis. This evidence concerns the gene STAT3 and ovarian carcinoma.